Agios Pharmaceuticals is expected to report Q3 2026 revenue of $9.11 million and a loss per share of $1.32, with its current $46.60 share price trading significantly below the $58.75 analyst consensus target. Investors are primarily focused on the commercial trajectory of Pyrukynd, specifically its net product revenue performance as the company transitions toward its next growth phase.
Recent clinical progress in the ENERGIZE and ENERGIZE-T Phase 3 trials for Thalassemia has heightened expectations for an NDA submission by the end of the year. Furthermore, the company’s massive $1.1 billion cash infusion from the vorasidenib royalty sale provides a robust runway to support upcoming commercial launches through 2026.